CHEST Clinical Trials Opportunities

Sponsoring company: Kymera Therapeutics
Disease state: asthma

The purpose of the KT621-AS-202 (BREADTH) trial is to assess the efficacy and safety profile of multiple doses of an investigational oral pill, KT-621, in participants with moderate to severe eosinophilic asthma.

BREADTH is a phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging trial enrolling approximately 264 participants to receive the trial drug or placebo. The total duration of participation will last about 21 weeks, including a screening period (up to five weeks), double-blind treatment period (12 weeks), and follow-up period (four weeks). After completing treatment in the BREADTH trial, eligible participants may choose to enroll in a 52-week open-label extension (OLE) trial assessing the long-term effects of KT-621, provided the OLE trial is available at their site. The investigational trial drug, KT-621, is an oral pill taken daily.

CLINICALTRIALS.GOV LINK »

Sponsoring company: Trevi Therapeutics
Disease states: idiopathic pulmonary fibrosis, chronic cough

This phase 3, multinational, randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of oral nalbuphine extended-release (NAL ER) in adults with idiopathic pulmonary fibrosis (IPF)-related chronic cough. Participants will be randomly assigned 2:1 to receive oral NAL ER 54 mg or placebo, administered twice daily for 54 weeks. Dosing is titrated over the first two weeks, followed by a fixed-dose treatment period of 52 weeks. Clinic visits occur approximately monthly, with a three-week safety follow-up by phone upon completion.

Assessments include periodic 24-hour ambulatory cough monitoring, electronic patient-reported outcome questionnaires, and monitoring of adverse events throughout the trial.

CLINICALTRIALS.GOV LINK »

STUDY LINK »